Immedica

Immedica Pharma is a fast-growing private niche pharmaceutical company headquartered in Stockholm, Sweden. It was established in 2018 as an evolution of the specialty pharma business of its parent company, Impilo. The company's focus is on the commercialization of niche specialty care and rare disease drugs, acquiring, and in-licensing late-stage or launched products for these markets. Immedica operates across Europe and the Middle East, serving as a commercial partner for pharmaceutical companies needing to reach patients in these regions. Its portfolio includes products for genetic and metabolic diseases, hematology and oncology, and specialty care. A key product in their portfolio is Ravicti®, used for the treatment of urea cycle disorders (UCDs). Immedica has also expanded its commercialization rights for certain products into the Middle East and North Africa (MENA) region through partnerships, such as the one with Vector Pharma FZCO.

The company's business model is centered on providing a commercial infrastructure for niche pharmaceuticals, managing the entire commercialization process from regulatory approval to patient access. Immedica generates revenue through the sale of these specialized medicines within its operational territories. The company has demonstrated significant growth, with revenues reaching SEK 767 million in 2021. Immedica has established itself as a key player in the European specialty pharma market, with a presence in over 50 countries. Keywords: specialty pharma, rare diseases, niche medicines, commercialization partner, European pharma, Middle East pharma, specialty care, drug licensing, orphan drugs, pharmaceutical sales